NYSE:HAE

Stock Analysis Report

Executive Summary

Haemonetics Corporation, a healthcare company, provides hematology products and solutions.


Snowflake Analysis

Proven track record with reasonable growth potential.


Similar Companies

Share Price & News

How has Haemonetics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HAE's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.6%

HAE

11.3%

US Medical Equipment

5.3%

US Market


1 Year Return

10.1%

HAE

-4.5%

US Medical Equipment

-10.7%

US Market

Return vs Industry: HAE exceeded the US Medical Equipment industry which returned -4.5% over the past year.

Return vs Market: HAE exceeded the US Market which returned -10.7% over the past year.


Shareholder returns

HAEIndustryMarket
7 Day1.6%11.3%5.3%
30 Day-9.9%-8.5%-13.6%
90 Day-13.6%-15.6%-19.8%
1 Year10.1%10.1%-3.8%-4.5%-8.9%-10.7%
3 Year145.7%145.7%47.0%43.0%15.5%8.0%
5 Year121.8%121.8%78.8%60.2%35.2%20.4%

Price Volatility Vs. Market

How volatile is Haemonetics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Haemonetics undervalued compared to its fair value and its price relative to the market?

26.8%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: HAE ($99.65) is trading below our estimate of fair value ($136.22)

Significantly Below Fair Value: HAE is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: HAE is poor value based on its PE Ratio (63.6x) compared to the Medical Equipment industry average (39x).

PE vs Market: HAE is poor value based on its PE Ratio (63.6x) compared to the US market (13.1x).


Price to Earnings Growth Ratio

PEG Ratio: HAE is poor value based on its PEG Ratio (2.3x)


Price to Book Ratio

PB vs Industry: HAE is overvalued based on its PB Ratio (8.7x) compared to the US Medical Equipment industry average (3x).


Next Steps

Future Growth

How is Haemonetics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

28.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HAE's forecast earnings growth (28% per year) is above the savings rate (1.7%).

Earnings vs Market: HAE's earnings (28% per year) are forecast to grow faster than the US market (12.3% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: HAE's revenue (6.2% per year) is forecast to grow slower than the US market (7.2% per year).

High Growth Revenue: HAE's revenue (6.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: HAE's Return on Equity is forecast to be high in 3 years time (28.9%)


Next Steps

Past Performance

How has Haemonetics performed over the past 5 years?

41.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HAE has a large one-off loss of $54.5M impacting its December 28 2019 financial results.

Growing Profit Margin: HAE's current net profit margins (8%) are higher than last year (4.8%).


Past Earnings Growth Analysis

Earnings Trend: HAE's earnings have grown significantly by 41.6% per year over the past 5 years.

Accelerating Growth: HAE's earnings growth over the past year (74.1%) exceeds its 5-year average (41.6% per year).

Earnings vs Industry: HAE earnings growth over the past year (74.1%) exceeded the Medical Equipment industry 1%.


Return on Equity

High ROE: HAE's Return on Equity (13.9%) is considered low.


Next Steps

Financial Health

How is Haemonetics's financial position?


Financial Position Analysis

Short Term Liabilities: HAE's short term assets ($582.6M) exceed its short term liabilities ($256.7M).

Long Term Liabilities: HAE's short term assets ($582.6M) exceed its long term liabilities ($406.5M).


Debt to Equity History and Analysis

Debt Level: HAE's debt to equity ratio (66.2%) is considered high.

Reducing Debt: HAE's debt to equity ratio has increased from 51.4% to 66.2% over the past 5 years.

Debt Coverage: HAE's debt is well covered by operating cash flow (34.8%).

Interest Coverage: HAE's interest payments on its debt are well covered by EBIT (10.2x coverage).


Balance Sheet

Inventory Level: HAE has a high level of physical assets or inventory.

Debt Coverage by Assets: HAE's debt is covered by short term assets (assets are 1.5x debt).


Next Steps

Dividend

What is Haemonetics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HAE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate HAE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HAE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HAE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HAE's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure


CEO

Chris Simon (55yo)

3.92s

Tenure

US$8,550,810

Compensation

Mr. Christopher A. Simon, also known as Chris, has been the Chief Executive Officer and President of Haemonetics Corporation since May 16, 2016. He joined Haemonetics in May 2016. Mr. Simon served as a Sen ...


CEO Compensation Analysis

Compensation vs Market: Chris's total compensation ($USD8.55M) is about average for companies of similar size in the US market ($USD7.33M).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Christopher Simon
CEO, President & Director3.92yrsUS$8.55m0.51% $25.5m
William Burke
CFO & Executive VP3.67yrsUS$2.31mno data
Michelle Basil
Executive VPno dataUS$2.15m0.0074% $369.9k
Jacqueline Scanlan
Senior Vice President of Global Human Resources3.08yrsUS$1.49m0.0087% $436.6k
Dan Goldstein
Principal Accounting Officer4yrsno data0.0049% $244.1k
Gerard Gould
Vice President of Investor Relations8.67yrsno datano data
Francis Tan
Senior Vice President of Corporate Development & Planning2.83yrsno datano data
Ian Purdy
Senior Vice President of Global Quality & Regulatory Affairs3.08yrsno datano data
Kevin O'Kelly-Lynch
Senior Vice President of Global Business Services3yrsno datano data
David Gueundjian
President of International2.92yrsno datano data

3.1yrs

Average Tenure

51yo

Average Age

Experienced Management: HAE's management team is considered experienced (3.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Christopher Simon
CEO, President & Director3.92yrsUS$8.55m0.51% $25.5m
Robert Abernathy
Independent Director2.5yrsUS$245.06k0.0058% $289.7k
Richard Meelia
Independent Chairman8.83yrsUS$419.94k0.057% $2.9m
Ronald Gelbman
Lead Directorno dataUS$262.94k0.093% $4.7m
Ellen Zane
Independent Director2.25yrsUS$249.94k0.0026% $129.8k
Claire Pomeroy
Independent Director1yrno datano data
Mark Kroll
Independent Director14.25yrsUS$245.06k0.041% $2.0m
Catherine Burzik
Independent Director3.5yrsUS$254.80k0.017% $857.2k
Charles Dockendorff
Independent Director5.75yrsUS$266.94k0.034% $1.7m

3.9yrs

Average Tenure

67yo

Average Age

Experienced Board: HAE's board of directors are considered experienced (3.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: HAE insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Haemonetics Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Haemonetics Corporation
  • Ticker: HAE
  • Exchange: NYSE
  • Founded: 1971
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$5.013b
  • Shares outstanding: 50.30m
  • Website: https://www.haemonetics.com

Number of Employees


Location

  • Haemonetics Corporation
  • 125 Summer Street
  • Boston
  • Massachusetts
  • 2110
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HAENYSE (New York Stock Exchange)YesCommon StockUSUSDMay 1991
HAZDB (Deutsche Boerse AG)YesCommon StockDEEURMay 1991

Biography

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. It operates through Japan, EMEA, North America Plasma, and All Other segments. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables, such as plasma collection containers and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; OrthoPAT, a perioperative autotranfusion system for orthopedic procedures; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital’s blood bank information system. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/01 06:57
End of Day Share Price2020/03/31 00:00
Earnings2019/12/28
Annual Earnings2019/03/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.